Bringing Hope: Testing Kinisoquin™ to Prevent Blood Clots in Cancer Patients
NCT06861088 · RecruitingThis trial is looking at how well Kinisoquin™ works to prevent blood clots in patients with metastatic or locally advanced pancreatic cancer. Patients in this study will receive either Kinisoquin™ or a placebo, which is a fake treatment. The goal is to see if Kinisoquin™ can help lower the risk of blood clots, especially after starting chemotherapy. Blood clots can happen often in these patients, especially in the first few months after treatment begins.
Locations and contact
This trial is running at 3 locations in the United States. All of them are currently recruiting.
United States3 locations · 3 recruiting
- Beth Israel Deaconess Medical CenterBoston, MassachusettsRecruiting
- Clavis Medical, LLCMiami Lakes, FloridaRecruiting
- Ventura Clinical TrialsVentura, CaliforniaRecruiting
Who can join
Adults aged 18 and older with confirmed pancreatic cancer that is either metastatic or locally advanced can join. Participants must be starting their first round of chemotherapy. They should not have any serious bleeding issues or take blood thinners. The trial is open to everyone regardless of race or other factors. The trial team will confirm who can participate.
What happens during the trial
Participants will be randomly placed into one of three groups. One group will receive Kinisoquin™ at 1000mg, another will get 2000mg of Kinisoquin™, and the last group will receive a placebo. Everyone will take their assigned treatment daily for 16 weeks. The study aims to find out which dose of Kinisoquin™ works best to prevent blood clots.
The trial team
This trial is sponsored by Quercis Pharma AG, which is responsible for running the study.
Important dates
The trial started on December 19, 2025, and is currently enrolling new participants. It is expected to finish by October 31, 2029.
Additional information
The trial's ID number is NCT06861088. This is a Phase 3 trial, meaning it is testing how well the treatment works and its safety. The study is FDA-regulated and aims to include about 480 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →